Compare HWKN & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | BEAM |
|---|---|---|
| Founded | 1938 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 1995 | 2019 |
| Metric | HWKN | BEAM |
|---|---|---|
| Price | $147.99 | $30.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $200.00 | $50.75 |
| AVG Volume (30 Days) | 139.2K | ★ 2.0M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | 12.26 | ★ 82.31 |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $974,431,000.00 | $24,000.00 |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | $6.30 | $32.20 |
| P/E Ratio | $47.40 | ★ N/A |
| Revenue Growth | 6.01 | ★ 33.33 |
| 52 Week Low | $117.51 | $15.52 |
| 52 Week High | $186.15 | $36.44 |
| Indicator | HWKN | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 69.32 |
| Support Level | $142.77 | $23.71 |
| Resistance Level | $154.95 | $31.54 |
| Average True Range (ATR) | 5.01 | 1.67 |
| MACD | -0.15 | 0.86 |
| Stochastic Oscillator | 31.34 | 87.74 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.